Is Teva Pharmaceutical Industries Limited (TEVA) Strengthening Its Neurology Portfolio With New Austedo Results?

TheFly reported connected June 8 that TEVA announced caller objective and real-world findings supporting the usage of Austedo and Austedo XR successful patients with tardive dyskinesia. Results from the IMPACT-TD survey showed that patients with mild symptoms experienced improvements successful involuntary movements and regular functioning aft treatment. The institution besides reported updated information from the ongoing three-year RIM-TD study, wherever much than fractional of participants achieved a attraction effect by week 15, portion further patients showed benefits with continued therapy beyond that period. The findings highlighted the imaginable worth of semipermanent attraction and reinforced Teva's efforts to amended illness absorption and outcomes for individuals surviving with tardive dyskinesia.

Second, it was announced connected June 4 that Teva Pharmaceutical Industries Limited (NYSE:TEVA) expanded its footprint successful planetary markets done the European rollout of AHZANTIVE, an aflibercept biosimilar. The motorboat began crossed respective countries, including France, Germany, Spain, and the Netherlands, with further marketplace entries planned aboriginal successful the year. The merchandise broadens TEVA's biosimilars portfolio and strengthens its presumption successful ophthalmology. Approved for aggregate retinal disorders, AHZANTIVE offers an further attraction enactment for patients with vision-threatening conditions. The motorboat besides reflects TEVA's strategy of expanding entree to biologic medicines done partnerships, commercialized expansion, and a increasing biosimilars business.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is simply a planetary pharmaceutical institution advancing its maturation strategy done generic GLP-1 treatments. By launching generic versions of liraglutide-based weight-loss and diabetes drugs, Teva aims to amended affordability and entree successful the increasing obesity attraction market.

While we admit the imaginable of TEVA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.